RabaVert was administered after temperature excursion; This case was reported by a nurse via licensee and described the occurrence of incorrect storage of drug in a patient who received Rabies NVS (RabAvert) for prophylaxis.   Co-suspect products included rabies vaccine needle device (Rabavert Needle Device) injection needle for prophylaxis and rabies vaccine pre-filled syringe device (Rabavert Pre-Filled Syringe Device) injection syringe for prophylaxis.   On an unknown date, the patient received RabAvert, Rabavert Needle Device and Rabavert Pre-Filled Syringe Device. On an unknown date, unknown after receiving RabAvert, Rabavert Needle Device and Rabavert Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional information was provided as follows: The age at vaccination was not reported. The nurse called for temperature excursion information. They had a fridge issue. She stated she believed after the first excursion they did use the vaccine, but she did not have any patient information and would have to run a report, which led to incorrect storage of drug.  The vaccine had not been given after 2nd excursion. Nurse stated they were made aware of an excursion on 3rd November2020 and then new excursion a day before reporting. First excursion max9.3 degrees C less than 15 minutes. Second excursion max 10.65 degrees C for 15 minutes. It was unknown if the vaccination was pre exposure or post.  Case reference number US-BN-2020-019887 is a spontaneous case report initially received from a nurse on 17-Mar-2020, and concerns a 7-year-old male patient.  The patient's medical history and concomitant medication details were not provided.  On 03-Nov-2020, RabAvert vial was affected to temperature excursion (Product storage error).  On 10-Nov-2020, the patient started therapy with RabaVert (Inactivated Rabies Virus Vaccine, Batch no. ARBA731A) at unknown dosage regimen for post-exposure prophylaxis.   On 17-Nov-2020, patient received second dose of RabaVert (Inactivated Rabies Virus Vaccine, Batch no. ARBA731A) at unknown dosage regimen for post-exposure prophylaxis.   On 24-Nov-2020, patient received third dose of RabaVert (Inactivated Rabies Virus Vaccine, Batch no. ARBA731A) at unknown dosage regimen for post-exposure prophylaxis.   At the time of this report it was not known whether the patient developed any adverse event.  Follow up information received from healthcare professional on 17-Mar-2021.  New information included updated patient's details (age, gender, initials) and indication (post-exposure prophylaxis).  This case is linked with cases US-BN-2021-000243 and US-BN-2021-000244 (same reporter).  Further information was not provided.; Reporter's Comments: Product storage error is listed by convention. Reportedly, the patient received RabAvert that was affected to temperature excursion which is considered to be product storage error. No adverse events were reported. Product storage error is not related to the suspect product but to human action.; Sender's Comments: Product storage error is listed by convention. Reportedly, the patient received RabAvert that was affected to temperature excursion which is considered to be product storage error. No adverse events were reported. Product storage error is not related to the suspect product but to human action.